Ritu Bansal

Ritu Bansal

Auto-generated profile, based on publicly available information

Ritu Bansal

Dermatology and Venereology Division, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
MMMansi Manchanda
Mansi Manchanda
MTMonica Torres
Monica Torres
FIFarydah Inuossa
Farydah Inuossa
RBRitu Bansal
Ritu Bansal
RKRahul Kumar
Rahul Kumar
JWJakob D Wikstrom
Jakob D Wikstrom
Impaired skin wound healing is a significant global health issue, especially among the elderly. Wound healing is a well-orchestrated process involving the sequential phases of inflammation, proliferation and tissue remodeling. Whilst wound healing is a highly dynamic and energy-requiring process, the role of metabolism remains largely unexplored. By combined transcriptomics and metabolomics of human skin biopsy samples, we mapped the core bioenergetic metabolic changes in normal acute as well as chronic wounds in elderly subjects. We found upregulation of glycolysis, tricarboxylic acid (TCA) cycle, glutaminolysis, and β-oxidation in later stages of acute wound healing and in chronic wounds. To ascertain the role of these metabolic pathways on wound healing, we targeted each pathway in a wound healing assay as well as in a human skin explant model using metabolic inhibitors and stimulants. Enhancement or inhibition of glycolysis and to a lesser extent glutaminolysis had a far greater impact on wound healing than similar manipulations of oxidative phosphorylation (OXPHOS) and fatty acid β-oxidation. These findings increase the understanding of wound metabolism and identifies glycolysis and glutaminolysis as potential targets for therapeutic intervention.

26 July 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
MHMatthew Hunt
Matthew Hunt
NWNuoqi Wang
Nuoqi Wang
NPNaricha Pupinyo
Naricha Pupinyo
PCPhilip Curman
Philip Curman
MTMonica Torres
Monica Torres
JWJakob D Wikstrom
Jakob D Wikstrom
Darier disease (DD) is a rare severe acantholytic skin disease caused by mutations in the ATP2A2 gene that encodes for the sarco/endoplasmic reticulum calcium ATPase isoform 2 (SERCA2). SERCA2 maintains endoplasmic reticulum calcium homeostasis by pumping calcium into the ER, critical for regulating cellular calcium dynamics and cellular function. To date, there is no treatment that specifically targets the disease mechanisms in DD. Dantrolene sodium (Dl) is a ryanodine receptor antagonist that inhibits calcium release from ER to increase ER calcium levels and is currently used for non-dermatological indications. In this study, we first identified dysregulated genes and molecular pathways in DD patient skin, demonstrating downregulation of cell adhesion and calcium homeostasis pathways, as well as upregulation of ER stress and apoptosis. We then show in various in vitro models of DD and SERCA2 inhibition that Dl aided in the retention of ER calcium and promoted cell adhesion. In addition, Dl treatment reduced ER stress and suppressed apoptosis. Our findings suggest that Dl specifically targets pathogenic mechanisms of DD and may be a potential treatment.